Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in adults over 70 years old

The advent of reduced-intensity conditioning regimens, improvements in graft-versus-host disease prophylaxis, and better supportive care have permitted increasing use of allogeneic hematopoietic cell transplantation (allo-HCT) in adults aged ≥70 years with acute myeloid leukemia. However, although potentially curative, nonrelapse mortality and relapse represent the main causes of treatment failure, highlighting the importance of refining both patient selection and transplant strategies. At the same time, continuously evolving nontransplant therapies and transplant technologies mandate prospective trials (re-)examining the role of allo-HCT and its optimal delivery.